The Montana-based Crow Tribe last week approved an ordinance to oversee its own cannabis cultivation and sales, and allow the tribe to benefit from the proceeds, the Associated Press reports.
Articles
MindMed To Commence Trading on Nasdaq
MindMed Inc (CAN:MMED / US:MMEDF) has received approval to commence trading on the NASDAQ starting April 27th. Symbol: MNMD.
Champignon Brands Announces Revocation of Cease Trade Orders
Champignon Brands has had its Cease Trade Order lifted and can resume trading on the CSE effective April 23, 2021 (symbol: SHRM).
Countdown To The atai IPO Begins: atai Files For $100m IPO Financing
With atai Life Sciences filing for a $100 million IPO financing, the countdown to IPO day has begun.
Minnesota Marijuana Legalization Bill Clears Eighth Committee On Route To The House Floor
An eighth Minnesota House committee on Thursday approved a bill to legalize marijuana in the state.
Louisiana Lawmakers Approve Bill To Legalize Medical Marijuana Flower For Patients
A bill to allow medical marijuana patients in Louisiana to access raw cannabis flower cleared a key House committee on Thursday—two days after the full chamber approved complementary legislation on taxing those products if they are legalized.
Cybin Demonstrates Proof of Concept of Its Deuterated Tryptamines for the Treatment of Depression and Addiction
Cybin has successfully demonstrated proof of concept for two new drug candidates in internal testing as it moves toward IND status.
MINDCURE (CSE: MCUR | OTC: MCURF) Partners its iSTRYM Technology with LUCID to Discover and Create Proprietary Music Experiences for Use During Psychedelic-Assisted Therapy Sessions
LUCID’s technology platform unites music, AI and research in neuroscience to create personalized digital music therapy managed in real-time by therapists based on patient feedback
Déjà Vu: 2021 Slump In Psychedelic Stocks Mirrors 2020
Low share prices. VERY low trading volumes. The slump in psychedelic stocks in 2021 looks a lot like the slump in 2020.
Psychedelics are transforming the way we understand depression and its treatment
Mental illness is the 21st century’s leading cause of disability, affecting an estimated billion people across the world.
Cybin Establishes Clinical Advisory Board of Renowned Physicians, Dr. Maurizio Fava, Dr. Lynn Marie Morski and Dr. Anthony Back
Cybin adds several experts in mental health to its Clinical Advisory Board.
New House Bills Would Make Cannabis Businesses Eligible For Federal Small-Business Aid
Lawmakers in the U.S. House of Representatives have introduced three new bills to make state-legal marijuana businesses eligible for federal small business services, including loans, disaster relief and grant programs.
U.S. House Approves Marijuana Banking Bill For Fourth Time, Setting Up Senate Consideration
The U.S. House of Representatives on Monday approved a bill to protect banks that service state-legal marijuana businesses from being penalized by federal regulators.
Psilocybin’s complicated relationship with creativity revealed in new placebo-controlled neuroimaging study
People under the influence of psilocybin — the active component of magic mushrooms — report having more profound and original thoughts, but tend to score lower on cognitive tests of creative ability, according to new research published in Translational Psychiatry.
Scientists Compared Psilocybin Against Antidepressants For The First Time
WHY AREN’T PEOPLE with depression prescribed magic mushrooms instead of Zoloft or Prozac?